NEW YORK (GenomeWeb News) – The November merger of Invitrogen and Applied Biosystems to form Life Technologies has been valued at $5.1 billion, down from the initial estimate of $6.7 billion.

Life Technologies disclosed in a filing with the US Securities and Exchange Commission yesterday that the value of Life Technologies shares issued in the transaction was around $1.8 billion, while the cash portion of the deal was roughly $3.2 billion. ABI shareholders received a total of approximately 80.8 million of the combined company's shares.